15th Jun 2020 13:57
Open Orphan PLC - pharmaceutical services company - First human trial of mosquito saliva vaccine AGS-v in human shows the vaccine to be safe and able to induce "a strong immune response in healthy volunteers". Findings suggest the vaccine is ready to advance to phase 2. The vaccine is designed to provoke an immune response to mosquito saliva in order to protect against misquito-borne diseases present in the saliva such as Malaria, Zika, Dengue Fever, and West Nile Virus.
Current stock price: 12.13 pence
Year-to-date change: up more than 100%
By Anna Farley; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
ORPH.L